Profound Medical Reports Exceptional Revenue Growth for Q3 2025

Profound Medical Reports Exceptional Revenue Growth

Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) recently announced impressive results indicating substantial revenue growth for the third quarter of 2025. As a dynamic player in the medical device sector, Profound focuses on developing innovative, AI-enabled therapies that provide incision-free solutions for diseased tissue ablation. According to their preliminary findings, the company is set to achieve revenues between $5.2 million and $5.3 million, marking an extraordinary increase of approximately 84% to 87% compared to $2.8 million earned during the same period last year.

Significant Revenue Growth and Projections

Preliminary reports from Profound Medical indicate that their gross margin is expected to reach about 72%, a notable increase from 64% in the previous year's quarter. This growth showcases the company’s strong market position and effective revenue-generating strategies. Arun Menawat, the CEO and Chairman of Profound, expressed enthusiasm regarding the figures, emphasizing the continued evolution of their TULSA-PRO system. This advanced technology not only enhances the installed base but also increases existing system utilization, contributing to the all-time revenue high.

TULSA-PRO System Highlights

The TULSA-PRO system stands out as a revolutionary treatment method utilizing real-time MRI guidance combined with AI-driven planning and sophisticated ultrasound technology. This precision approach allows for effective prostate tissue ablation while preserving vital functions such as urinary continence and sexual performance. Profound's installed base for TULSA-PRO systems has increased from 60 to 67, with expectations to expand to at least 75 installations by year-end, bolstered by a robust sales pipeline.

Upcoming Financial Results and Conference Call

Profound Medical plans to release full financial results for the third quarter of 2025 after market close on the designated date in November. Following the release, a conference call will occur at 4:30 PM ET, where company management will detail these results and share insights on business developments. Enthusiasts and stakeholders can participate in the conference call live or access it afterward through Profound's website, ensuring transparency and engagement with their investor community.

Company Profile

Established as a leader in the medical device industry, Profound Medical is pioneering incision-free therapies. They commercialize the TULSA Procedure®, and while it is focused primarily on prostate health, their advancements imply broader applications in the future. This includes the potential for non-invasive treatments for a variety of conditions, showcasing their commitment to innovative healthcare solutions.

Innovation beyond TULSA

Besides TULSA-PRO, Profound is also advancing the Sonalleve® platform, which is gaining traction for its applications in treating uterine fibroids and alleviating pain from bone metastases. This technology, now CE marked and approved for various indications, sees expanded interest for its promising capabilities in oncology applications.

Commitment to Excellence

Profound Medical's dedication to excellence and innovation highlights its position in the healthcare market. The company aims to leverage its technologies not only for prostate health but also to explore further applicable therapeutic areas. By prioritizing research and development, Profound is set to navigate the complexities of the medical device sector and respond effectively to evolving healthcare needs.

Frequently Asked Questions

What is Profound Medical's primary focus?

Profound Medical specializes in developing incision-free therapies for diseased tissue ablation, notably in prostate health.

What are the revenue expectations for Q3 2025?

Profound projects revenues between $5.2 million and $5.3 million for the third quarter, marking significant growth year-over-year.

When will full financial results be announced?

The complete financial results will be released after market close on a date in November, with a conference call to follow.

What is the TULSA-PRO system?

TULSA-PRO is a medical device that utilizes real-time MRI and AI technologies for targeted ablation of prostate tissue.

Does Profound Medical have plans for future innovations?

Yes, Profound Medical is actively exploring additional treatment methodologies within its existing technology platforms, including Sonalleve®.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.